Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 11Recurrence 8Lymphoma, Large B-Cell, Diffuse 6Sezary Syndrome 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Leukemia 3Hodgkin Disease 3Waldenstrom Macroglobulinemia 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoblastic Lymphadenopathy 2Glioma 2Glioblastoma 2Colorectal Neoplasms 2Breast Neoplasms 2Thyroid Neoplasms 1Thyroid Diseases 1Stomach Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1

Interventions

Doxorubicin 5Cyclophosphamide 5Vincristine 4Prednisone 4Brentuximab Vedotin 4Etoposide 3etoposide phosphate 2Prednisolone 2Bortezomib 2tazemetostat 1prednylidene 1pembrolizumab 1duvelisib 1deltacortene 1Vorinostat 1Panobinostat 1Nivolumab 1Methylprednisolone 1Melphalan 1Gemcitabine 1Cytarabine 1Cisplatin 1Carmustine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Enteropathy-Associated T-Cell Lymphoma × Panobinostat × Clear all
NCT00901147 2014-06-27

Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

Singapore General Hospital

Phase 2 Completed
25 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡